Practice parameter update: Management issues for women with epilepsy - Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society

Neurology

Volumn 73, Issue 2, 2009, Pages 133-141

  Harden, C L ^a   Meador, K J ^c   Pennell, P B ^c   Hauser, W A ^e   Gronseth, G S ^g   French, J A ^d   Wiebe, S ^f   Thurman, D ^h   Koppel, B S ⁱ   Kaplan, P W ^j   Robinson, J N ^k   Hopp, J ^b   Ting, T Y ^b   Gidal, B ^l   Hovinga, C A ^m   Wilner, A N ⁿ   Vazquez, B ^o   Holmes, L ^k   Krumholz, A ^b   Finnell, R ^p   Hirtz, D ^q   Le Guen, C ^r   more..

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c EMORY UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF WISCONSIN MADISON   (United States)

^m UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁿ New York University ^*

^o NEW YORK UNIVERSITY   (United States)

^p TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^q NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ADVERSE OUTCOME; COGNITION; CONGENITAL MALFORMATION; EPILEPSY; EVIDENCE BASED MEDICINE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL CARE; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TERATOGENESIS; BIRTH WEIGHT; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG EFFECT; FEMALE; NEWBORN; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RISK;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; BIRTH WEIGHT; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RISK; VALPROIC ACID;

EID: 68149143987     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a6b312     Document Type: Article

References (40)

1. United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Bridged-Race Population Estimates, United States. July 1st resident population by state, county, age, sex, bridged-race, and Hispanic origin on CDC WONDER On-line Database. Available at: http://wonder.cdc.gov. Accessed June 2008.
2. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the "common" neurologic disorders? Neurology 2007;68:326-337.
3. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000;55:S21-S31.
4. Harden CL, Hopp J, Ting TY, et al. Practice Parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73:126-132.
5. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-1138.
6. Fried S, Kozer E, Nulman I, Einarson TR, Koren G. Malformation rates in children of women with untreated epilepsy. Drug Safety 2004;27:197-202.
7. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004;93:1774-1776.
8. Puho EH, Szunyogh M, Metneki J, Czeizel AE. Drug treatment during pregnancy and isolated orofacial clefts in Hungary. Cleft Palate Craniofac J 2007;4:194-202.
9. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 2000;41:1436-1443.
10. Morrow J, Russell A, Guthrie E, et al. Malformations risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198.
11. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005;64:1874-1878.
12. Samrén EB, van Duijn CM, Christiaens GCML, Hofman A, Lindhout E. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-746.
13. Vajda FJE, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 2006;13:645-654.
14. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006;67:407-412.
15. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999;40:1231-1236.
16. Wyszynski WF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965.
17. Agresti A. Categorical Data Analysis (Wiley Series in Probability and Statistics), 2nd edition. Malden, MA: Wiley-Interscience; 2002.
18. Mawer G, Clayton-Smith J, Coyle H, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002;11:512-518.
19. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42 (suppl 5):119-125.
20. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-990.
21. Bertollini R, Mastoiacovo P, Segni G. Maternal epilepsy and birth defects: a case-control study in the Italian Multicenter Registry of Birth Defects (IPIMC). Eur J Epidemiol 1985;1:67-72.
22. Sattler JM. Assessment of Children revised/updated. 3rd ed. San Diego: Jerome M. Sattler; 1992.
23. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995;274:1518-1525.
24. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32.
25. Holmes LB, Rosenberger PB, Harvey EA, Khoshbin S, Ryan L. Intelligence and physical features of children of women with epilepsy. Teratology 2000;61:196-202.
26. Koch S, Titze K, Zimmermann RB, Schröder M, Lehmkuhl U, Rauh H. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999;40:1237-1243.
27. Oyen N, Vollset SE, Eide MG, Bjerkedal T, Skjærven R. Maternal epilepsy and offspring's adult intelligence: a population-based study from Norway. Epilepsia 2007;48:1731-1738.
28. Hirano T, Fujioka K, Okada M, Iwasa H, Kaneko S. Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia 2004;45(suppl 8):53-57.
29. Gaily E, Kantola-Sorsa E, Granström ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990;32:403-414.
30. Wide K, Henning E, Tomson T, Winbladh B. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 2002;91:409-414.
31. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-1583.
32. Eriksson K, Viinikainen K, Mönkkönen A, et al. Children exposed to valproate in utero: population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 2005;65:189-200.
33. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767-770.
34. Vanoverloop D, Schnell RR, Harvey EA, Holmes LB. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992;14:329-335.
35. Lösche G, Steinhausen HC, Koch S, Helge H. The psychological development of children of epileptic parents: II: the differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 1994;83:961-966.
36. Hvas CL, Henriksen TB, Ostergaard JR, Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birth weight. Br J Obstet Gynaecol 2000;107:896-902.
37. Viinikainen K, Heinonen S, Eriksson K, Kalviainan R. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006;47:186-192.
38. Hiilesmaa VK, Bardy A, Teramo K. Obstetric outcome in women with epilepsy. Am J Obstet Gynecol 1985;152:499-504.
39. Richmond JR, Krishnamoorthy P, Andermann E, Benjamin A. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004;190:371-379.
40. Laskowska M, Leszczyriska-Gorzelak B, Oleszczuk J. Pregnancy in women with epilepsy. Gynecol Obstet Invest 2001;51:99-102.